8-K: ASPAC III Acquisition Corp. Announces Definitive Merger Agreement with Bioserica International Limited in $200 Million Stock Deal

ASPAC III Acquisition Corp. has entered into a definitive merger agreement to combine with Bioserica International Limited, a bio-based antimicrobial materials company, in a transaction valued at $200 million to be paid entirely in stock, with potential for additional earnout shares.

Summary

• A SPAC III Acquisition Corp. (Parent) has entered into a definitive merger agreement with Bioserica International Limited (Company), a British Virgin Islands business company specializing in bio-based antimicrobial materials.
• The transaction involves a two-step merger process: first, a 'Reincorporation Merger' where Parent merges into A SPAC III Mini Acquisition Corp. (Purchaser), with Purchaser as the surviving entity.
• Second, an 'Acquisition Merger' will occur where A SPAC III Mini Sub Acquisition Corp. (Merger Sub) merges into Bioserica, with Bioserica surviving as a wholly-owned subsidiary of Purchaser.
• The aggregate consideration for existing Bioserica shareholders and equity award holders is $200,000,000, which will be paid entirely in stock.
• This consideration will comprise newly issued Class B Ordinary Shares of the Purchaser at a price of $10.00 per share, plus such number of Purchaser Class A Ordinary Shares as determined by the Merger Agreement, up to a maximum of 1,786,000 Purchaser Class A Ordinary Shares.
• An earnout provision allows for the issuance of up to an additional 4,000,000 Purchaser Class A Ordinary Shares to Bioserica shareholders (Earnout Shareholders) based on specific triggers.
• Earnout Event 1: If the VWAP of Purchaser Class A Ordinary Shares reaches or exceeds $15.00 for any 20 trading days within a 30-trading day period between 1 and 24 months after the Closing Date, 1,000,000 Earnout Shares will be issued.
• Earnout Event 2: If consolidated revenue of Purchaser and its Subsidiaries reaches or exceeds $50,000,000 by the first full fiscal year after the Closing Date, 1,000,000 Earnout Shares will be issued.
• Earnout Event 3: If consolidated revenue reaches or exceeds $100,000,000 by the second full fiscal year after the Closing Date, 2,000,000 Earnout Shares will be issued (less any shares already issued under Earnout Event 2).
• Earnout Event 4: If consolidated revenue reaches or exceeds $200,000,000 by the third full fiscal year after the Closing Date, 3,000,000 Earnout Shares will be issued (less any shares already issued under Earnout Event 2 and/or Earnout Event 3).
• The transaction is contingent upon various closing conditions, including the SEC declaring the registration statement effective, obtaining required shareholder approvals, and the completion of China Securities Regulatory Commission (CSRC) filings and Cyberspace Administration of China (CAC) cybersecurity review.
• The Parent's trust fund holds at least $60,000,000 for the benefit of its public shareholders.
• A lock-up agreement will restrict the transfer of certain Purchaser Ordinary Shares for a period of 365 days after the closing date, with a 20% early release if the stock price reaches $15.00 after 180 days.
• A previously announced agreement with HDEducation Group Limited was mutually terminated on May 21, 2025.

Sentiment

Score: 7

Explanation: The filing announces a definitive merger agreement, a crucial step for a SPAC. The terms are laid out, including a substantial valuation and earnout potential, which are positive. However, the transaction is subject to multiple regulatory approvals (SEC, CSRC, CAC) and shareholder votes, and specific termination clauses related to these, indicating material execution risks. The termination of a prior agreement also adds a slight cautionary note.

Positives

• A definitive merger agreement has been reached, signaling a clear path forward for the SPAC to complete its business combination.
• The target company, Bioserica International Limited, operates in the bio-based antimicrobial materials sector, aligning with growing market demand for sustainable and health-focused products.
• The acquisition consideration is entirely in stock, which aligns the long-term interests of Bioserica's existing shareholders with the future performance of the combined public entity.
• The inclusion of earnout provisions provides a strong incentive for Bioserica's management to achieve specific stock price and revenue growth targets post-merger, potentially enhancing shareholder value.
• The Parent's trust fund holds at least $60,000,000, providing a substantial capital base for the transaction and future operations.
• The Reincorporation Merger is intended to qualify as a Section 368 reorganization for U.S. federal income tax purposes, which could offer tax efficiencies.
• Key personnel of Bioserica are expected to execute employment agreements, suggesting continuity in management and operations post-merger.
• The Purchaser Class A Ordinary Shares are expected to be conditionally approved for listing on Nasdaq upon closing, ensuring continued public market access.

Negatives

• The transaction is subject to numerous and complex closing conditions, including regulatory approvals from the SEC, CSRC, and CAC, as well as shareholder votes, which introduce significant execution risk and potential for delays or failure.
• Specific termination clauses allow for the agreement to be abandoned if audited financials are not delivered by May 31, 2025, or if the closing does not occur by October 30, 2025, creating tight deadlines.
• The cybersecurity review filing with the CAC and potential rejection by the CSRC are critical regulatory hurdles that could prevent the transaction from closing.
• A 365-day lock-up period on certain Purchaser Ordinary Shares, even with a potential 20% early release, may limit liquidity for some shareholders post-merger.
• The mutual termination of a previous agreement with HDEducation Group Limited on May 21, 2025, indicates a prior failed business combination attempt by the SPAC.

Risks

• The inability of A SPAC III Acquisition Corp. and Bioserica to consummate the business combination within the time provided in the SPAC's organizational documents.
• The actual performance of Bioserica's business post-merger may differ materially from expectations.
• The risk that the approval of the Company's shareholders for the Business Combination is not obtained.
• Failure to realize the anticipated benefits of the Business Combination, including as a result of a delay in consummating the Business Combination.
• The level of redemptions made by the Company's shareholders and its impact on the amount of funds available in the Company's trust account to complete the business combination.
• Risks relating to the combined company's sources of cash and cash resources.
• Risks relating to the combined company's ability to manage future growth effectively.
• The effects of competition on the combined company's future business and market position.
• The outcome of any potential litigation, government and regulatory proceedings, and any investigations and inquiries involving the parties to the transactions.
• The impact of pandemics, global conflicts, the global economic status, or tariffs on Bioserica's or the combined company's business.
• The cybersecurity review filing for overseas listing undertaken with the CAC being revoked or otherwise no longer in effect.
• The transaction being rejected by the CSRC pursuant to the CSRC Trial Rules.
• Uncertainties with respect to indirect transfers of equity interests in PRC resident enterprises by their non-PRC holding companies regarding stock transfer, sales, use, real estate transfer, or other similar taxes.

Future Outlook

The combined company intends to file a registration statement (Form F-4) with the SEC, which will include a preliminary proxy statement for shareholder approval and a prospectus for the securities to be issued. The Reincorporation Merger is intended to qualify as a reorganization under Section 368 of the Code for U.S. federal income tax purposes. The Purchaser will adopt an equity incentive plan for the Company's management, providing for 5% of the then outstanding Purchaser Class A Ordinary Shares (on a fully diluted basis) to be available for grant. The Purchaser Class A Ordinary Shares to be issued in connection with the Closing are expected to be conditionally approved for listing on Nasdaq. The Company Group will provide audited consolidated financial statements for the fiscal year ended December 31, 2024, by May 31, 2025, and unaudited but reviewed consolidated financial statements for the first six months of each year within 90 calendar days following the end of that period.

Management Comments

• "The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law."
• "The parties intend that the Reincorporation Merger qualify as a reorganization within the meaning of Section 368 of the Code."
• "The officers and directors of the Reincorporation Surviving Corporation are fully authorized... to take... all such lawful and necessary action, so long as such action is not inconsistent with this Agreement."
• "The officers and directors of the Surviving Corporation are fully authorized... to take... all such lawful and necessary action, so long as such action is not inconsistent with this Agreement."
• "The Company Group acknowledges that a substantial portion of the filings with the SEC... shall include disclosure regarding the Company Group and its management, operations and financial condition."
• "The Company Group will... cooperate with the Purchaser Parties, respond to questions... and provide any information requested by the Purchaser Parties in connection with any filing with the SEC."
• "The Company Group acknowledge and agree that they are aware... of the restrictions imposed by U.S. federal securities laws... on a Person possessing material nonpublic information about a publicly traded company."
• "The Company hereby agrees that it shall not purchase or sell any securities of the Parent in violation of such Laws, or cause or encourage any Person to do the foregoing."

Industry Context

The transaction involves a Special Purpose Acquisition Company (SPAC) combining with a private operating company, Bioserica International Limited, which specializes in bio-based antimicrobial materials. This reflects a continuing trend of SPACs seeking to merge with private companies to bring them public. The focus on 'bio-based antimicrobial materials' suggests an alignment with growing global demand for sustainable and health-conscious products, particularly in light of increased awareness of hygiene and material safety. The involvement of Chinese regulatory bodies (CSRC, CAC) highlights the complexities and additional regulatory hurdles associated with cross-border transactions involving Chinese entities, especially concerning data security and overseas listings.

Comparison to Industry Standards

• The $200 million valuation for Bioserica, paid entirely in stock, is a specific deal term. Without comparable company valuations or industry-specific multiples (e.g., revenue multiples for antimicrobial materials companies), a direct assessment against global benchmarks is difficult.
• The earnout structure, tied to both stock price performance ($15.00 target) and revenue growth ($50M, $100M, $200M targets), is a common mechanism in SPAC transactions to align incentives and provide contingent consideration based on post-merger performance. These revenue targets would need to be compared against growth rates of similar companies in the bio-based materials or specialty chemicals sector.
• The lock-up period of 365 days with a 180-day early release at $15.00 is a standard practice in SPAC deals to ensure stability post-combination, though the specific terms can vary.
• The D&O tail insurance premium cap of 300% of the last full fiscal year's premium is a specific financial protection for directors and officers, which can be compared to industry norms for similar-sized transactions and risk profiles.

Management Changes

Corporate Governance

Legal Proceedings

• The Company Group represents that there is no Action (or any basis therefore) pending against, or threatened against or affecting, the Company Group, any of its Key Personnel, the Business, or any Company Ordinary Shares, or any of the Company Groups assets or any Contract that would reasonably be expected to have a Material Adverse Effect.
• No outstanding judgments against the Company Group that would reasonably be expected to have a Material Adverse Effect on the Company's ability to perform its obligations under the agreement.
• Each member of the Company Group is not, and has not been in the past two (2) years, subject to any proceeding with any Authority that would reasonably be expected to have a Material Adverse Effect.
• No Authority has commenced or threatened to initiate any Action against the Company Group to enjoin the marketing, sale, offer, distribution or provision of any Service.
• Since January 1, 2023, no member of the Company Group has received any written or oral allegation, assertion or claim with respect to accounting, internal accounting controls, auditing practices, procedures, methodologies or methods, or unlawful accounting or auditing matters.
• Since January 1, 2023, no internal investigations with respect to accounting, auditing or revenue recognition have been conducted by any member of the Company Group.

Related Party Transactions

• Except for employment relationships, agreements relating to the purchase of the Company's equity securities, and/or the payment of cash or equity compensation, benefits, and expense reimbursements and advances in the ordinary course of business, and as disclosed in Section 5.34 of the Company Disclosure Schedule, no director or executive officer (or equivalent) of the Company Group has or has had directly or indirectly an economic interest in any Top Customer or Top Supplier, or any contractual arrangement with the Company Group (other than indemnity arrangements or directors and officers liability insurance coverage).
• Material transactions between a member of the Company Group and any shareholder, officer, employee, or director of the Company Group or any Affiliate of any such Person are represented to be arms-length transactions with fair market price and not impairing the interests of the Company Shareholders, or duly approved by the board of directors.
• The Company Group has not, since January 1, 2023, extended or maintained credit, arranged for the extension of credit, or renewed an extension of credit in the form of a personal loan to or for any director or executive officer (or equivalent) of the Company Group, or materially modified any term of any such extension or maintenance of credit.
• To the knowledge of the Company Group, there are no contracts or legally binding arrangements between the Company Group and any family member of any director or executive officer (or equivalent) of the Company Group.
• Except for Contracts with any Service Providers (including employee offer letters), there are no contracts, side letters, legally binding arrangements or understandings between the Company Group and any other person holding capital of the Company, which grant or purport to grant any board observer or governance rights.

Stakeholder Impact

• **Shareholders (Parent):** Will vote on the proposed merger and have redemption rights for their shares. Their investment will transition from a SPAC to a combined operating company, Bioserica, with potential for future growth.
• **Shareholders (Bioserica):** Will receive $200 million in Purchaser stock as consideration and are eligible for additional earnout shares based on performance, aligning their future financial interests with the combined entity. They will also be subject to a lock-up period on their shares.
• **Employees (Bioserica):** Key personnel are expected to execute new employment agreements, suggesting continuity in leadership. An equity incentive plan will be established for management, providing a stake in the combined company's success.
• **Customers and Suppliers:** The Company Group has covenanted to preserve intact its business relationships with clients and suppliers, and no material adverse changes or terminations from top customers or suppliers have been reported, indicating stable operational relationships.
• **Regulatory Bodies (SEC, CSRC, CAC):** The transaction requires significant filings and approvals from these bodies, highlighting their critical oversight role and potential impact on the transaction's completion and the combined entity's future operations.

Next Steps

• Parent and Bioserica intend to jointly file a registration statement (Form F-4) with the SEC, including a preliminary proxy statement and prospectus.
• The SEC must declare the registration statement effective.
• Parent will mail a definitive proxy statement to its shareholders.
• A special meeting of Parent shareholders will be held to approve the proposed transactions and other matters.
• Bioserica shareholders must authorize and approve the Merger Agreement and transactions.
• Bioserica must deliver audited consolidated financial statements for fiscal year ended December 31, 2024, by May 31, 2025.
• Bioserica must complete the CSRC filing and obtain necessary certificates/receipts.
• Key personnel of Bioserica must execute employment agreements.
• The Purchaser Class A Ordinary Shares to be issued must be conditionally approved for listing on Nasdaq.
• The Reincorporation Merger and Acquisition Merger will be consummated.
• The Purchaser will enter into an amended and restated registration rights agreement and a lock-up agreement with certain shareholders.
• The Purchaser will prepare an incentive plan for Bioserica management.

Key Dates

Keywords

SPAC, Merger Agreement, Business Combination, Bioserica International Limited, Antimicrobial Materials, SEC Filing, 8-K, Nasdaq, Earnout, Trust Account, Corporate Governance, Risk Factors, China Securities Regulatory Commission, Cyberspace Administration of China, Lock-up Agreement, Registration Rights, Public Company Accounting Oversight Board, British Virgin Islands